What We Do
What It Is
What it does
For the treatment of CRAO, nanobubbles are introduced into the eye by intravitreal injection. The nanobubbles then disperse through the vitreous and make their way to the retina. Here, the shells of the nanobubbles are denatured/disintegrated to release oxygen encapsulated at the core of the nanobubble, safely delivering oxygen to the surrounding tissue to revive the cells from hypoxia.
Who it is for
The Rox technology is currently focused on CRAO with potential future applications to treat other ocular ischemic conditions.